Which companies overlap with IRCCS Centro di Riferimento Oncologico della Basilicata's portfolio?

Top competitors by shared drug class: Celgene.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/irccs-centro-di-riferimento-oncologico-della-basilicata.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

IRCCS Centro di Riferimento Oncologico della Basilicata — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IRCCS Centro di Riferimento Oncologico della Basilicata pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lenalidomide, dexamethasone	Lenalidomide, dexamethasone	phase 3	Immunomodulatory agent + corticosteroid	Cereblon (CRBN); glucocorticoid receptor	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celgene · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IRCCS Centro di Riferimento Oncologico della Basilicata:

Cite this brief

Drug Landscape (2026). IRCCS Centro di Riferimento Oncologico della Basilicata — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/irccs-centro-di-riferimento-oncologico-della-basilicata. Accessed 2026-05-17.